Holocene Advisors LP Has $2.10 Million Holdings in LivaNova PLC (NASDAQ:LIVN)

Holocene Advisors LP grew its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 432.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 39,944 shares of the company’s stock after acquiring an additional 32,445 shares during the period. Holocene Advisors LP owned 0.07% of LivaNova worth $2,099,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Point72 Asset Management L.P. increased its holdings in shares of LivaNova by 204.3% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company’s stock valued at $70,479,000 after acquiring an additional 863,157 shares during the last quarter. First Light Asset Management LLC lifted its position in LivaNova by 591.1% in the second quarter. First Light Asset Management LLC now owns 710,390 shares of the company’s stock worth $38,944,000 after purchasing an additional 607,598 shares during the period. Great Lakes Advisors LLC acquired a new stake in shares of LivaNova during the 2nd quarter valued at about $16,614,000. Driehaus Capital Management LLC grew its stake in shares of LivaNova by 64.7% in the 2nd quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock valued at $29,824,000 after purchasing an additional 213,749 shares during the period. Finally, The Manufacturers Life Insurance Company grew its position in LivaNova by 286.4% in the third quarter. The Manufacturers Life Insurance Company now owns 207,248 shares of the company’s stock valued at $10,889,000 after acquiring an additional 153,611 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Price Performance

Shares of NASDAQ LIVN opened at $49.71 on Friday. The stock has a market capitalization of $2.70 billion, a price-to-earnings ratio of 118.36 and a beta of 0.98. LivaNova PLC has a fifty-two week low of $43.15 and a fifty-two week high of $64.47. The business has a 50-day moving average of $52.19 and a 200-day moving average of $51.86. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on LIVN shares. Mizuho dropped their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Robert W. Baird increased their price target on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. The Goldman Sachs Group assumed coverage on shares of LivaNova in a research note on Friday, October 4th. They set a “buy” rating and a $65.00 price objective on the stock. StockNews.com cut LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 16th. Finally, Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $69.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.